EnteroMedics Eyes First Commercial Maestro Implants For Obesity After Months Of Prep
This article was originally published in The Gray Sheet
The company says its training and facility certification efforts are on track to support commercial implants by June. The next challenge will be gaining broad-based reimbursement, as the first procedures are expected to be funded by self-pay or one-off local coverage.
You may also be interested in...
As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.
Three years in the making, FDA has released a final guidance for medical device development tools that would allow developers to qualify their MDDTs and give medical device manufactures access to new tools that could help them prove safety and effectiveness of their products sooner.
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.